Trump plans generic drug tariffs from 2028 with two-year delay testing U.S. onshoring push

The latest tariff salvo underscored Trump's goal of reshoring low-cost drug production, but displacing established suppliers like India won't be easy.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.